Isis to Gain Almost $4M from Alnylam s Deal with Novartis | GenomeWeb

NEW YORK, Sept. 12 (GenomeWeb News) - Isis Pharmaceuticals expects nearly $4 million in payments from Alnylam Pharmaceuticals following Alnylam's recent deal with Novartis, the Carlsbad, Calif.-based company said today.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.